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Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–
dexamethasone in relapsed multiple myeloma by previous
treatment
MA Dimopoulos1, AK Stewart2, T Masszi3, I Špička4, A Oriol5, R Hájek6, L Rosiñol7, D Siegel8, GG Mihaylov9, V Goranova-Marinova10,
P Rajnics11, A Suvorov12, R Niesvizky13, A Jakubowiak14, J San-Miguel15, H Ludwig16, S Ro17, S Aggarwal17, P Moreau18 and A Palumbo19
Carfilzomib, a proteasome inhibitor, is approved as monotherapy and in combination with dexamethasone or lenalidomide–
dexamethasone (Rd) for relapsed or refractory multiple myeloma. The approval of carfilzomib–lenalidomide–dexamethasone (KRd) was
based on results from the randomized, phase 3 study ASPIRE (NCT01080391), which showed KRd significantly improved progression-free
survival (PFS) vs Rd (median 26.3 vs 17.6 months; hazard ratio (HR) =0.690; P=0.0001). This subgroup analysis of ASPIRE evaluated KRd vs
Rd by number of previous lines of therapy and previous exposure to bortezomib, thalidomide or lenalidomide. Treatment with KRd led to
a 12-month improvement in median PFS vs Rd after first relapse (HR 0.713) and a 9-month improvement after ⩾2 previous lines of
therapy (HR 0.720). Treatment with KRd led to an approximate 8-month improvement vs Rd in median PFS in bortezomib-exposed
patients (HR 0.699), a 15-month improvement in thalidomide-exposed patients (HR 0.587) and a 5-month improvement in lenalidomide-
exposed patients (HR 0.796). Objective response and complete response or better rates were higher with KRd vs Rd, irrespective of
previous treatment. KRd had a favorable benefit–risk profile and should be considered an appropriate treatment option for patients with
1 or ⩾2 previous lines of therapy and those previously exposed to bortezomib, thalidomide or lenalidomide.
Blood Cancer Journal (2017) 7, e554; doi:10.1038/bcj.2017.31; published online 21 April 2017
INTRODUCTION
Important patient- and disease-specific factors, including previous
treatments, are considered when selecting a second- or third-line
therapy for patients with relapsed multiple myeloma (MM).1,2 In
the United States, bortezomib- and lenalidomide-based regimens
are the most commonly used first- and second-line therapies
for patients with MM;3 these regimens also are endorsed by
international clinical guidelines.2,4
As patients progress through multiple lines of bortezomib- and
lenalidomide-based regimens in early lines of therapy, they may
develop treatment-resistant disease. One study in patients with
relapsed MM reported a median duration of response of
approximately 10 months in patients with one prior regimen
and a median duration of response of approximately 6 months in
patients with three prior regimens.5 Given the prognostic value of
the number of previous lines of therapy and the frequent use of
bortezomib and lenalidomide as front-line therapy, there is a
critical need to evaluate the clinical effect of previous treatment
on the efficacy and safety of novel treatment strategies used for
patients with relapsed MM.
Carfilzomib is a selective and irreversible epoxyketone
proteasome inhibitor that is approved in the United States for
use in combination with dexamethasone or lenalidomide plus
dexamethasone for the treatment of patients with relapsed or
refractory MM (1–3 previous lines of therapy) and as a single
agent for the treatment of patients with relapsed or refractory
MM (1 or more previous lines of therapy); the agent has also
been approved in Europe for use in combination with
lenalidomide and dexamethasone (Rd) for the treatment of
patients with MM who have received at least one previous line
of therapy.6 The approvals for the combination of carfilzomib,
lenalidomide and dexamethasone (KRd) were based on results
from a preplanned interim analysis of the randomized, phase 3
ASPIRE trial, which evaluated KRd vs Rd in patients with relapsed
MM (1–3 previous lines of therapy). Treatment with KRd led to a
significant reduction in the risk of disease progression or death
when compared with Rd (hazard ratio (HR) 0.69; 95% confidence
interval (95% CI): (0.57, 0.83); P = 0.0001), demonstrating the
superiority of KRd vs Rd for the primary endpoint of
progression-free survival (PFS). The overall response rate (ORR)
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was higher in the KRd group vs the Rd group (87.1% (95% CI:
83.4, 90.3) vs 66.7% (95% CI: 61.8, 71.3); odds ratio, 3.47 (95% CI:
2.41, 5.00)), including a complete response (CR) or better in
31.8% and 9.3% of patients in the two groups, respectively.
Patients in the KRd group consistently reported superior health-
related quality of life relative to those in the Rd group during
18 cycles of treatment.7
As the treatment of patients with relapsed and/or refractory MM
who have received multiple lines of therapy is challenging, we
performed a subgroup analysis of the interim results from the
ASPIRE study to evaluate the efficacy and safety of KRd vs Rd by
the number of previous lines of therapy (1 vs ⩾ 2), previous
exposure to bortezomib, thalidomide or lenalidomide, and
refractory status to bortezomib, thalidomide or lenalidomide in
any previous regimen.
MATERIALS AND METHODS
Study design and patients
ASPIRE was a randomized, open-label, phase 3 study that evaluated KRd vs
Rd in adults with relapsed MM (1–3 previous lines of therapy). Patients
previously treated with bortezomib were eligible if they did not experience
disease progression during therapy; patients previously treated with
lenalidomide were eligible provided they did not discontinue treatment
owing to adverse effects, have disease progression during the first
3 months of therapy with Rd, or have progression at any time during
treatment if Rd was their most recent treatment. All patients provided
written informed consent.
The primary endpoint was PFS in the intent-to-treat (ITT) population.
Secondary endpoints included overall survival, ORR, health-related
quality of life and safety. Here we present the subgroup analyses of
PFS and ORR. Overall survival was not included in this subgroup analysis,
as the data were not mature and were awaiting final analysis. The
subgroup analysis for PFS and ORR by prior lines, prior exposure and
disease resistance were preplanned; however, results are for hypothesis-
generating purposes are not adjusted for multiplicity. Thus, they should
be interpreted descriptively. The study protocol was approved by the
institutional review boards or ethics committees of all participating sites
and was conducted in accordance with the International Conference on
Harmonisation Guidelines for Good Clinical Practice and the Declaration
of Helsinki. ASPIRE is registered with ClinicalTrials.gov (NCT01080391).
Full details regarding the ASPIRE study design have been published.7
Assessments
Disease progression and treatment response were assessed centrally in
blinded manner by an independent review committee in accordance with
Table 1. Baseline demographic and clinical characteristics (ITT population)
Characteristic 1 previous line of therapy ⩾ 2 previous lines of therapy
KRd
n= 184
Rd
n= 157
KRd
n=212
Rd
n=239
Median age, years (range) 65.0 (40.0–87.0) 66.0 (40.0–91.0) 62.0 (38.0–87.0) 64.0 (31.0–87.0)
Age cohort, n (%)
18–64 years 86 (46.7) 68 (43.3) 125 (59.0) 120 (50.2)
⩾ 65 years 98 (53.3) 89 (56.7) 87 (41.0) 119 (49.8)
ECOG PS, n (%)
≤ 1 163 (88.6) 145 (92.4) 193 (91.0) 216 (90.4)
2 21 (11.4) 12 (7.6) 19 (9.0) 23 (9.6)
Cytogenetic riska, n (%)
High 23 (12.5) 18 (11.5) 25 (11.8) 34 (14.2)
Standard 70 (38.0) 72 (45.9) 77 (36.3) 98 (41.0)
Unknown 91 (49.5) 67 (42.7) 110 (51.9) 107 (44.8)
Creatinine clearance
Mean± s.d., ml/min 83.0± 26.2 80.6± 27.7 86.7± 31.1 89.4± 31.3
Distribution, n (%)
30 to o50 ml/min 8 (4.3) 21 (13.4) 17 (8.0) 10 (4.2)
⩾ 50 ml/min 175 (95.1) 134 (85.4) 195 (92.0) 224 (93.7)
Unknown/other 1 (0.5) 2 (1.3) 0 5 (2.1)
Serum β2-microglobulin, n (%)
o 2.5 mg/l 35 (19.0) 24 (15.3) 42 (19.8) 53 (22.2)
⩾ 2.5 mg/l 149 (81.0) 133 (84.7) 170 (80.2) 186 (77.8)
Previous therapy, n (%)b
Bortezomib 93 (50.5) 73 (46.5) 168 (79.2) 187 (78.2)
Refractory to bortezomib in any previous regimenc 20 (10.9) 6 (3.8) 40 (18.9) 52 (21.8)
Thalidomide 64 (34.8) 52 (33.1) 112 (52.8) 119 (49.8)
Refractory to thalidomide in any previous regimenc 10 (5.4) 15 (9.6) 51 (24.1) 50 (20.9)
Lenalidomide 34 (18.5) 21 (13.4) 45 (21.2) 57 (23.8)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group Performance Status; ITT, intent-to-treat; KRd, carfilzomib, lenalidomide and dexamethasone; Rd,
lenalidomide and dexamethasone. aThe high-risk group consisted of patients with the genetic subtype t(4;14) or t(14;16) or with deletion 17p in 60% or more
of plasma cells, according to central review of bone marrow samples obtained at study entry. The standard-risk group consisted of patients without t(4;14) or
t(14;16) and with deletion 17p in o60% of plasma cells. bPatients must not have progressed during the first 3 months of treatment with prior Rd or
progressed at any time if Rd was the most recent line of prior treatment. If a patient progressed during any bortezomib-containing regimen, they were eligible
to enroll if the progression date occurred after discontinuation of bortezomib. cRefractory disease was defined as less than a minimal response to, or
progression during therapy or within 60 days after completion of therapy.
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International Myeloma Working Group Uniform Response Criteria.8
Minimal response was defined according to European Group for Blood
and Marrow Transplant criteria.9,10
The incidence and severity of adverse events (AEs) were recorded until
30 days after the last dose of study treatment. AEs were graded according
to the National Cancer Institute Common Terminology Criteria for Adverse
Events (v4.0).11
Statistical analysis
Efficacy analyses were based on the ITT population. The safety
population included all patients who received ⩾ 1 dose of study
treatment. Subgroups were defined based on dichotomous baseline
variables: previous lines of therapy (1 vs ⩾ 2), previous treatment with
bortezomib (yes vs no), previous treatment with thalidomide (yes vs no),
previous treatment with lenalidomide (yes vs no), refractory status to any
previous bortezomib treatment (yes vs no), refractory status to
thalidomide (yes vs no) in any previous regimen and refractory status
to lenalidomide any previous regimen (yes vs no). Reported P-values for
this subgroup analysis are one-sided, unadjusted for multiple compar-
isons and are descriptive in nature.
RESULTS
Patient disposition
In total, 792 patients were enrolled and randomized to treatment
with KRd (n=396) or Rd (n=396), as previously reported.7 A total of
341 patients had received one prior line of therapy (KRd, n=184;
Rd, n=157), and 451 patients had received two or more prior lines
of therapy (KRd, n=212; Rd, n=239). Patients with 1 or ⩾ 2 previous
lines of therapy generally had similar baseline characteristics; within
these subgroups, baseline characteristics were also generally well-
balanced between the treatment arms (Table 1). However, baseline
demographics and disease characteristics may not be relevant at
the time of relapse. Median duration of treatment among patients
who had received one previous line of therapy was 83.0 weeks in
the KRd group and 64.0 weeks in the Rd group; among patients
who had received ⩾ 2 previous lines of therapy, median duration of
treatment was 90.6 weeks in the KRd group and 52.0 weeks in the
Rd group. Other important demographic and clinical characteristics
are summarized by previous lines of therapy (1 vs ⩾2) and
treatment group (KRd vs Rd) in Table 1.
1.0
0.8
0.6
0.4
P
ro
po
rti
on
 S
ur
vi
vi
ng
 w
ith
ou
t P
ro
gr
es
si
on
0.2
0.0
0 6 12 18 24
Months from Randomization
30 36 42 48
212
239
KRd
Rd
177
166
148
119
119
88
94
68
59
41
17
8
1
0
KRd
Rd
Number of Subjects at Risk:
Progression/Death, n (%) 
Median PFS, mo 
Hazard ratio (KRd/Rd) (95% CI) 
P value (1-sided) 
0.720 (0.561–0.923)
0.0046
KRd
(n=212)
116 (54.7)
25.8 (95% CI, 22.2–31.0)
Rd
(n=239)
136 (56.9)
16.7 (95% CI, 13.9–22.0)
1.0
0.8
0.6
0.4
P
ro
po
rti
on
 S
ur
vi
vi
ng
 w
ith
ou
t P
ro
gr
es
si
on
0.2
0.0
0 6 12 18 24
Months from Randomization
30 36 423 9 15 21 27 33 39 45 48
184
157
KRd
Rd
155
121
131
87
103
63
85
49
53
31
7
10 1
164
139
144
104
121
77
92
55
76
43
24
19
0
2
KRd
Rd
Number of Subjects at Risk:
Progression/Death, n (%) 
Median PFS, mo 
Hazard ratio (KRd/Rd) (95% CI) 
P value (1-sided) 
0.713 (0.532–0.957)
0.0118
KRd
(n=184)
91 (49.5)
29.6  (95% CI, 23.2–33.5)
Rd
(n=157)
88 (56.1)
17.6 (95% CI, 15.0–22.2)
Figure 1. Kaplan–Meier estimate of PFS in patients with (a) 1 previous line of therapy and (b) ⩾ 2 previous lines of therapy.
Table 2. Responses by previous lines of therapy (1 vs ⩾ 2) (ITT population)
1 previous line of therapy ⩾ 2 previous lines of therapy
KRd
n=184
Rd
n= 157
KRd
n= 212
Rd
n=239
Best overall response, n (%)a
sCR 23 (12.5) 5 (3.2) 33 (15.6) 12 (5.0)
CR 39 (21.2) 6 (3.8) 31 (14.6) 14 (5.9)
VGPR 78 (42.4) 57 (36.3) 73 (34.4) 66 (27.6)
PR 20 (10.9) 42 (26.8) 48 (22.6) 62 (25.9)
ORR, n (%)a 160 (87.0) 110 (70.1) 185 (87.3) 154 (64.4)
95% CIb 81.2–91.5% 62.2–77.1% 82.0–91.4% 58.0–70.5%
OR for KRd vs Rd (95% CI) 2.85 (1.65–4.93) 3.78 (2.33–6.13)
Abbreviations: CI, confidence interval; CR, complete response; ITT, intent-to-treat; KRd, carfilzomib, lenalidomide and dexamethasone; OR, odds ratio; ORR,
overall response rate; PR, partial response; Rd, lenalidomide and dexamethasone; sCR, stringent complete response; VGPR, very good partial response.
aDetermined by independent review committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR
had a best overall response of PR or better. bClopper− Pearson interval.
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In all, 521 patients (65.8%) had received previous bortezomib
(KRd, n= 261; Rd, n= 260); 118 (14.9%) had disease refractory to
bortezomib in any previous regimen (KRd, n= 60; Rd, n= 58). In
total, 347 (43.8%) had received previous thalidomide (KRd, n= 176,
Rd, n= 171); 126 (15.9%) were refractory to thalidomide in any
previous regimen (KRd, n= 61; Rd, n= 65) and 157 patients (19.8%)
had received previous lenalidomide (KRd, n= 79; Rd, n= 78).
A total of 57 patients (7.2%) were refractory to lenalidomide in any
Figure 2. Kaplan–Meier estimate of PFS in patients with (a) previous bortezomib exposure, (b) no previous bortezomib exposure, (c) previous
thalidomide exposure, (d) no previous thalidomide exposure, (e) previous lenalidomide exposure and (f) no previous lenalidomide exposure.
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previous regimen, 26 (3.3%) were refractory to bortezomib and
lenalidomide in any previous regimen and 33 (4.2%) were
refractory to bortezomib and thalidomide in any previous
regimen.
The cutoff date for the interim analysis was 16 June 2014.7
Efficacy by line of therapy
Consistent with the overall results for the ITT population, the
addition of carfilzomib to Rd reduced the risk of disease
progression or death in patients who had received 1 previous
line of therapy or ⩾ 2 previous lines of therapy (Figures 1a and b).
Among patients with one previous line of therapy, the median PFS
was 29.6 months in the KRd group and 17.6 months in the Rd
group (HR= 0.713; 95% CI: 0.532, 0.957; P= 0.0118). Among
patients with ⩾ 2 previous lines of therapy, the median PFS was
25.8 months in the KRd group and 16.7 months in the Rd group
(HR= 0.720; 95% CI: 0.561, 0.923; P= 0.0046).
Response rates by line of therapy are shown in Table 2.
Consistent with the overall results for the ITT population,7 among
patients who received one previous line of therapy, the ORR was
higher in the KRd group compared with the Rd group (87.0% vs
70.1%), with an odds ratio of 2.85 (95% CI: 1.65, 4.93). Similarly,
among patients who received ⩾ 2 previous lines of therapy, the
ORR was higher in the KRd group vs the Rd group (87.3% vs
64.4%), with an odds ratio of 3.78 (95% CI: 2.33, 6.13). Furthermore,
regardless of the number of previous lines of therapy, a larger
proportion of patients in the KRd achieved a CR or better than
those in the Rd group (1 previous line: 33.7% vs 7.0%; ⩾ 2 previous
lines: 30.2% vs 10.9%).
Efficacy by type of previous treatment
Also consistent with the overall results for the ITT population,
treatment with KRd resulted in longer PFS compared with Rd,
irrespective of previous exposure to bortezomib, thalidomide or
lenalidomide (Figures 2a–f). The median PFS for KRd vs Rd was
Table 3. Response by type of previous treatment (ITT population)
Previous bortezomib No previous bortezomib
KRd
n=261
Rd
n= 260
KRd
n= 135
Rd
n=136
Best overall response, n (%)
sCR 31 (11.9) 12 (4.6) 25 (18.5) 5 (3.7)
CR 47 (18.0) 13 (5.0) 23 (17.0) 7 (5.1)
VGPR 97 (37.2) 77 (29.6) 54 (40.0) 46 (33.8)
PR 50 (19.2) 63 (24.2) 18 (13.3) 41 (30.1)
ORR, n (%)a 225 (86.2) 165 (63.5) 120 (88.9) 99 (72.8)
95% CIb 81.4–90.1% 57.3–69.3% 82.3–93.6% 64.5–80.1%
OR for KRd vs Rd (95% CI) 3.60 (2.33–5.55) 2.99 (1.55–5.76)
Previous thalidomide No previous thalidomide
KRd
n=176
Rd
n= 171
KRd
n= 220
Rd
n=225
Best overall response, n (%)
sCR 32 (18.2) 8 (4.7) 24 (10.9) 9 (4.0)
CR 28 (15.9) 8 (4.7) 42 (19.1) 12 (5.3)
VGPR 63 (35.8) 41 (24.0) 88 (40.0) 82 (36.4)
PR 33 (18.8) 47 (27.5) 35 (15.9) 57 (25.3)
ORR, n (%)a 156 (88.6) 104 (60.8) 189 (85.9) 160 (71.1)
95% CIb 83.0− 92.9% 53.1− 68.2% 80.6− 90.2% 64.7− 76.9%
OR for KRd vs Rd (95% CI) 5.03 (2.88–8.78) 2.48 (1.54–3.99)
Previous lenalidomide No previous lenalidomide
KRd
n= 79
Rd
n=78
KRd
n= 317
Rd
n=318
Best overall response, n (%)
sCR 8 (10.1) 3 (3.8) 48 (15.1) 14 (4.4)
CR 11 (13.9) 1 (1.3) 59 (18.6) 19 (6.0)
VGPR 25 (31.6) 14 (17.9) 126 (39.7) 109 (34.3)
PR 20 (25.3) 21 (26.9) 48 (15.1) 83 (26.1)
ORR, n (%)a 64 (81.0) 39 (50.0) 281 (88.6) 225 (70.8)
95% CIb 70.6–89.0% 38.5–61.5% 84.6–91.9% 65.4–75.7%
OR for KRd vs Rd (95% CI) 4.27 (2.08–8.73) 3.23 (2.11–4.92)
Abbreviations: CI, confidence interval; CR, complete response; ITT, intent-to-treat; KRd, carfilzomib, lenalidomide and dexamethasone; OR, odds ratio; ORR,
overall response rate; PR, partial response; Rd, lenalidomide and dexamethasone; sCR, stringent complete response; VGPR, very good partial response.
aDetermined by Independent Review Committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR
had a best overall response of PR or better. bClopper− Pearson interval.
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24.4 vs 16.6 months for patients with previous bortezomib
exposure (n= 521; HR = 0.699; 95% CI: 0.556, 0.879; P= 0.0010)
and 30.3 vs 18.2 months for patients without previous
bortezomib exposure (n= 271; HR = 0.726, 95% CI: 0.518, 1.018;
P= 0.0313). The median PFS for KRd vs Rd was 29.6 vs
14.9 months for patients with previous thalidomide exposure
(n= 347; HR = 0.587, 95% CI: 0.441, 0.781; P= 0.0001), and 25.9 vs
18.9 months for patients without previous thalidomide exposure
(n= 445; HR = 0.824, 95% CI: 0.639, 1.061; P= 0.0663). The median
PFS for KRd vs Rd was 19.4 vs 13.9 months for patients with
previous lenalidomide exposure (n= 157; HR = 0.796; 95% CI:
0.522, 1.215; P= 0.1452) and 28.7 vs 17.7 months for patients
without previous lenalidomide exposure (n= 635; HR = 0.685;
95% CI: 0.554, 0.847; P= 0.0002).
A consistency of benefit for KRd vs Rd in terms of PFS was also
observed in patients with disease refractory to bortezomib,
thalidomide or lenalidomide in any previous regimen. The median
PFS for KRd vs Rd was 22.3 vs 19.4 months for patients with
disease refractory to bortezomib (HR = 0.799; 95% CI: 0.492, 1.297;
P= 0.1810), 24.1 vs 13.0 months for patients refractory to
thalidomide (HR = 0.599; 95% CI: 0.390, 0.918; P= 0.0089), and
11.3 vs 9.0 months for patients refractory to lenalidomide
(HR = 0.571; 95% CI: 0.283, 1.149; P= 0.0555).
Response by previous treatment is shown in Table 3. The
ORRs were 86.2% (KRd) vs 63.5% (Rd) in patients with previous
bortezomib exposure (odds ratio, 3.60 (95% CI: 2.33, 5.55)) and
88.9% (KRd) vs 72.8% (Rd) in patients without previous
bortezomib exposure (odds ratio, 2.99 (95% CI: 1.55, 5.76)). In
patients with previous thalidomide exposure, the ORRs were
88.6% (KRd) and 60.8% (odds ratio, 5.03 (95% CI: 2.88, 8.78)); in
patients without previous thalidomide exposure, the ORRs
were 85.9% vs 71.1% for KRd vs Rd (odds ratio, 2.48 (95% CI:
1.54, 3.99)). The ORRs were 81.0% (KRd) vs 50.0% (Rd) in
patients with previous lenalidomide exposure (odds ratio, 4.27
(95% CI: 2.08, 8.73)) and 88.6% (KRd) vs 70.8% (Rd) in patients
without previous lenalidomide exposure (odds ratio, 3.23 (95%
CI: 2.11, 4.92)). The rates of CR or better were 29.9% (KRd) vs
9.6% (Rd) in patients with previous bortezomib exposure and
35.6% (KRd) vs 8.8% (Rd) in patients without previous
bortezomib exposure. The rates of CR or better were 34.1%
(KRd) vs 9.4% (Rd) in patients with previous thalidomide
exposure and 30.0% (KRd) vs 9.3% (Rd) in patients without
previous thalidomide exposure. In patients with previous
lenalidomide exposure, the rates of CR or better were 24.1%
(KRd) vs 5.1% (Rd); in patients without previous lenalidomide
exposure, the rates of CR or better were 33.8% (KRd) vs 10.4%
(Rd). For patients refractory to bortezomib, thalidomide or
lenalidomide, the ORRs for KRd vs Rd were 80.0% vs 60.3%
(odds ratio, 2.63; 95% CI, 1.16–5.99), 86.9% vs 52.3% (odds
ratio, 6.04; 95% CI, 2.48–14.69) and 69.0% vs 25.0% (odds ratio,
6.67; 95% CI, 2.09–21.31), respectively.
Safety by lines of therapy
In the subgroups that received 1 and ⩾ 2 previous lines of therapy,
336 (KRd, n= 182; Rd, n= 154) and 445 patients (KRd, n= 210; Rd,
n= 235), respectively, received ⩾ 1 dose of study drug and were
evaluable for safety. Any grade AEs occurred in 97.8% (KRd) and
99.4% (Rd) of patients who received 1 previous line of therapy and
in 96.2% (KRd) and 95.7% (Rd) of patients who received ⩾ 2
previous lines of therapy. Common AEs and AEs of interest of any
grade by line of therapy are shown in Table 4. Notable AEs
included hypertension (preferred term; 1 previous line: 11.5%
(KRd) vs 4.5% (Rd); ⩾ 2 previous lines: 16.7% (KRd) vs 8.5% (Rd)),
acute renal failure (grouped term; 1 previous line: 11.0% (KRd) vs
6.5% (Rd); ⩾ 2 previous lines: 6.2% (KRd) vs 7.7% (Rd)) and dyspnea
(preferred term; 1 previous line: 23.1% (KRd) vs 14.3% (Rd); ⩾ 2
previous lines: 16.2% (KRd) vs 15.3% (Rd)).
Common AEs of grade ⩾ 3 by line of therapy are shown in
Table 5. AEs of grade ⩾ 3 occurred in 85.7% (KRd) and 79.9% (Rd)
of patients who received 1 previous line of therapy and in 81.9%
(KRd) and 81.3% (Rd) of patients who received ⩾ 2 previous lines
of therapy. No AEs of grade ⩾ 3 occurred ⩾ 5% more frequently
with KRd vs Rd in patients who received one previous line of
Table 4. Adverse events of any grade by lines of therapy (safety
population)
1 previous line of
therapy
⩾ 2 previous lines
of therapy
KRd
n=182
Rd
n= 154
KRd
n= 210
Rd
n=235
AEs occurring in ⩾ 10% of patients in any subgroup
(preferred terms), n (%)
Diarrhea 83 (45.6) 59 (38.3) 83 (39.5) 72 (30.6)
Anemia 82 (45.1) 66 (42.9) 85 (40.5) 89 (37.9)
Fatigue 65 (35.7) 45 (29.2) 64 (30.5) 74 (31.5)
Neutropenia 59 (32.4) 45 (29.2) 89 (42.4) 86 (36.6)
Muscle spasms 55 (30.2) 28 (18.2) 49 (23.3) 54 (23.0)
URTI 54 (29.7) 29 (18.8) 58 (27.6) 46 (19.6)
Cough 50 (27.5) 29 (18.8) 63 (30.0) 38 (16.2)
Pyrexia 49 (26.9) 33 (21.4) 63 (30.0) 48 (20.4)
Thrombocytopenia 49 (26.9) 32 (20.8) 65 (31.0) 56 (23.8)
Nasopharyngitis 48 (26.4) 28 (18.2) 36 (17.1) 35 (14.9)
Hypokalemia 45 (24.7) 25 (16.2) 63 (30.0) 27 (11.5)
Edema peripheral 45 (24.7) 28 (18.2) 40 (19.0) 47 (20.0)
Constipation 43 (23.6) 27 (17.5) 36 (17.1) 40 (17.0)
Dyspnea 42 (23.1) 22 (14.3) 34 (16.2) 36 (15.3)
Insomnia 38 (20.9) 23 (14.9) 37 (17.6) 40 (17.0)
Asthenia 35 (19.2) 29 (18.8) 35 (16.7) 27 (11.5)
Nausea 34 (18.7) 26 (16.9) 44 (21.0) 29 (12.3)
Hypocalcemia 33 (18.1) 16 (10.4) 30 (14.3) 29 (12.3)
Pneumonia 31 (17.0) 19 (12.3) 37 (17.6) 37 (15.7)
Bronchitis 29 (15.9) 21 (13.6) 45 (21.4) 33 (14.0)
Back pain 27 (14.8) 35 (22.7) 40 (19.0) 43 (18.3)
Hypophosphatemia 27 (14.8) 13 (8.4) 25 (11.9) 16 (6.8)
Hyperglycemia 26 (14.3) 17 (11.0) 23 (11.0) 21 (8.9)
Rash 25 (13.7) 23 (14.9) 27 (12.9) 37 (15.7)
Arthralgia 22 (12.1) 27 (17.5) 27 (12.9) 24 (10.2)
Dizziness 22 (12.1) 19 (12.3) 26 (12.4) 25 (10.6)
Pain in extremity 22 (12.1) 19 (12.3) 24 (11.4) 22 (9.4)
Headache 21 (11.5) 9 (5.8) 32 (15.2) 22 (9.4)
Hypertension 21 (11.5) 7 (4.5) 35 (16.7) 20 (8.5)
RTI 20 (11.0) 17 (11.0) 23 (11.0) 22 (9.4)
Vomiting 20 (11.0) 16 (10.4) 27 (12.9) 16 (6.8)
Decreased appetite 19 (10.4) 17 (11.0) 25 (11.9) 18 (7.7)
Bone pain 15 (8.2) 18 (11.7) 24 (11.4) 18 (7.7)
AEs of interest (grouped terms), n (%)
Cardiac failurea 10 (5.5) 8 (5.2) 15 (7.1) 8 (3.4)
Ischemic heart diseaseb 12 (6.6) 7 (4.5) 11 (5.2) 11 (4.7)
Acute renal failurec 20 (11.0) 10 (6.5) 13 (6.2) 18 (7.7)
Abbreviations: AE, adverse event; CAD, coronary artery disease; KRd,
carfilzomib, lenalidomide and dexamethasone; MI, myocardial infarction;
Rd, lenalidomide and dexamethasone; RTI, respiratory tract infection; URTI,
upper respiratory tract infection. aIncluded: cardiac failure, congestive
cardiac failure, pulmonary edema, hepatic congestion, cardiopulmonary
failure, acute pulmonary edema, acute cardiac failure and right ventricular
failure. bIncluded: angina pectoris, MI, acute MI, increased blood creatinine
phosphokinase, CAD, myocardial ischemia, coronary artery occlusion,
increased troponin, increased troponin T, acute coronary syndrome,
abnormal cardiac stress test, cardiomyopathy stress, unstable angina,
coronary artery stenosis, abnormal electrocardiogram ST-T segment and
abnormal electrocardiogram T wave. cIncluded: acute renal failure, renal
failure, renal impairment, azotemia, oliguria, anuria, toxic nephropathy and
prerenal failure.
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therapy. Hypokalemia was the only AE of grade ⩾ 3 that occurred
⩾ 5% more frequently with KRd (11.0%) vs Rd (3.4%) in patients
who received ⩾ 2 previous lines of therapy. In the KRd group,
neutropenia was the only grade ⩾ 3 AE that occurred ⩾ 5% more
frequently after ⩾ 2 previous lines of therapy (32.4%) vs 1 previous
line of therapy (26.4%).
Serious AEs were observed in 63.2% (KRd) and 53.9% (Rd) of
patients who received 1 previous line of therapy and 56.7% (KRd)
and 53.6% (Rd) of patients who received ⩾ 2 previous lines of
therapy. In total, 28.6% of KRd patients and 22.7% of Rd patients
who had received 1 previous line of therapy discontinued any
study drug owing to an AE; 23.8% of KRd patients and 26.4% of Rd
patients who had received ⩾ 2 previous lines of therapy
discontinued any study drug for this reason. Nine KRd patients
(4.9%) and nine Rd patients (5.8%) who had received one previous
line of therapy died while receiving study treatment or within
30 days of the last dose of study drug; 21 KRd patients (10.0%) and
24 Rd patients (10.2%) who had received ⩾ 2 previous lines of
therapy died while receiving study treatment.
Among patients who received one previous line of therapy, AEs
leading to permanent discontinuation of study treatment in two
or more patients in any subgroup were thrombocytopenia (KRd,
n= 0; Rd, n= 2), myocardial infarction (KRd, n= 2 (both grade 5);
Rd, n= 0), acute myocardial infarction (KRd, n= 2; Rd, n= 2), death
(KRd, n= 2; Rd, n= 1), fatigue (KRd, n= 0; Rd, n= 2), pneumonia
(KRd, n= 3; Rd, n= 0), acute myeloid leukemia (KRd, n= 2 (1 grade
5); Rd, n= 0), colon cancer (KRd, n= 2; Rd, n= 0) and rash (KRd,
n= 0; Rd, n= 2). Among patients who had received ⩾ 2 previous
lines of therapy, AEs leading to permanent discontinuation of
study treatment in two or more patients in any subgroup were
cardiac failure (KRd, n= 1 (grade 5); Rd, n= 2 (both grade 5)), septic
shock (KRd, n= 2 (1 grade 5 event); Rd, n= 1 (grade 5)), pneumonia
(KRd, n= 1 (grade 5); Rd, n= 3 (2 grade 5 events)), acute myeloid
leukemia (KRd, n= 0; Rd, n= 2 (1 grade 5 event)), myelodysplastic
syndrome (KRd, n= 0; Rd, n= 2 (both grade 5)), cerebrovascular
accident (KRd, n= 0; Rd, n= 2), acute renal failure (KRd, n= 0; Rd,
n= 2 (1 grade 5 event)) and pulmonary embolism (KRd, n= 0; Rd,
n= 2 (1 grade 5 event)).
DISCUSSION
This subgroup analysis of the ASPIRE study indicates that KRd
improved outcomes in patients in their first relapse (1 previous
line of therapy), patients with ⩾ 2 previous lines of therapy,
patients with or without previous exposure to bortezomib,
thalidomide or lenalidomide, and in patients refractory to
bortezomib or refractory to thalidomide. Given the challenges
of treatment in the relapsed and/or refractory setting, where
the efficacy of anti-MM agents often declines with successive
lines of therapy,5 it is an important finding that the HRs for
PFS consistently favored KRd across all the subgroups based
on previous treatment history. Treatment with KRd led to
a 12-month improvement in median PFS vs Rd after first relapse
and a 9-month improvement in median PFS vs Rd in patients
with ⩾ 2 previous lines of therapy, with comparable HRs.
Similarly, treatment with KRd led to an approximate 8-month
improvement vs Rd in patients with previous exposure to
bortezomib, a 3-month improvement in patients with disease
refractory to bortezomib, a 15-month improvement in patients
with previous thalidomide exposure, an 11-month improvement
in patients refractory to thalidomide, a 5-month improvement in
patients with previous lenalidomide exposure and a 2-month
improvement in patients refractory to lenalidomide. Patients in
the KRd group achieved a substantially higher CR or better rate
than those in the Rd group, irrespective of the number of
previous lines of therapy or the type of previous treatment. In
the KRd group, the rate of CR or better was consistent across the
number of previous lines of therapy and the type of previous
treatment.
As expected, in both treatment groups, absolute median PFS
and ORRs were observed to be generally better among patients
who had received less previous treatment exposure. In the KRd
group, lack of previous exposure to bortezomib, lack of
previous exposure to lenalidomide and having one previous
line therapy were associated with approximately 6-, 9- and 4-
month longer median PFS durations compared with those in
patients with previous exposure to bortezomib, previous
exposure to lenalidomide and ⩾ 2 previous lines of therapy,
respectively. In the Rd group, lack of previous exposure to
bortezomib, lack of previous exposure to lenalidomide, and
having one previous line therapy were associated with
approximately 2-, 4- and 1-month longer median PFS durations
compared with those in patients with previous exposure to
bortezomib, previous exposure to lenalidomide and ⩾ 2
previous lines of therapy, respectively. These findings are
consistent with a previous report on the clinical course of
patients with relapsed MM, where it was observed that the
Table 5. Adverse events grade⩾3 by lines of therapy (safety
population)
1 previous line of
therapy
⩾ 2 previous lines
of therapy
KRd
n= 182
Rd
n= 154
KRd
n= 210
Rd
n= 235
Grade⩾ 3 AEs occurring in⩾ 3% of patients in any subgroup
(preferred terms), n (%)
Neutropenia 48 (26.4) 34 (22.1) 68 (32.4) 69 (29.4)
Anemia 31 (17.0) 30 (19.5) 39 (18.6) 37 (15.7)
Thrombocytopenia 28 (15.4) 18 (11.7) 37 (17.6) 30 (12.8)
Pneumonia 22 (12.1) 16 (10.4) 27 (12.9) 25 (10.6)
Hypophosphatemia 18 (9.9) 8 (5.2) 15 (7.1) 10 (4.3)
Hypokalemia 14 (7.7) 11 (7.1) 23 (11.0) 8 (3.4)
Fatigue 13 (7.1) 10 (6.5) 17 (8.1) 15 (6.4)
Hyperglycemia 11 (6.0) 10 (6.5) 9 (4.3) 8 (3.4)
Cataract 10 (5.5) 4 (2.6) 5 (2.4) 6 (2.6)
Pulmonary embolism 8 (4.4) 4 (2.6) 4 (1.9) 5 (2.1)
RTI 8 (4.4) 3 (1.9) 8 (3.8) 5 (2.1)
Asthenia 7 (3.8) 5 (3.2) 7 (3.3) 3 (1.3)
Hypertension 7 (3.8) 1 (0.6) 10 (4.8) 6 (2.6)
Hypocalcemia 7 (3.8) 3 (1.9) 6 (2.9) 3 (1.3)
Insomnia 7 (3.8) 4 (2.6) 4 (1.9) 7 (3.0)
Diarrhea 6 (3.3) 6 (3.9) 9 (4.3) 10 (4.3)
Leukopenia 6 (3.3) 5 (3.2) 6 (2.9) 11 (4.7)
Lymphopenia 6 (3.3) 3 (1.9) 5 (2.4) 5 (2.1)
Decreased platelet count 6 (3.3) 3 (1.9) 6 (2.9) 6 (2.6)
Rash 4 (2.2) 5 (3.2) 1 (0.5) 1 (0.4)
Decreased neutrophil
count
4 (2.2) 1 (0.6) 8 (3.8) 10 (4.3)
Dyspnea 4 (2.2) 4 (2.6) 7 (3.3) 3 (1.3)
Syncope 3 (1.6) 2 (1.3) 2 (1.0) 8 (3.4)
AEs of interest (grouped terms), n (%)
Cardiac failurea 6 (3.3) 3 (1.9) 9 (4.3) 4 (1.7)
Ischemic heart diseaseb 9 (4.9) 2 (1.3) 4 (1.9) 6 (2.6)
Acute renal failurec 6 (3.3) 5 (3.2) 7 (3.3) 7 (3.0)
Abbreviations: AE, adverse event; KRd, carfilzomib, lenalidomide and
dexamethasone; MI, myocardial infarction; Rd, lenalidomide and dexa-
methasone; RTI, respiratory tract infection. aIncluded: cardiac failure,
congestive cardiac failure, pulmonary edema, hepatic congestion, cardio-
pulmonary failure, acute pulmonary edema, acute cardiac failure and right
ventricular failure. bIncluded: angina pectoris, MI, acute MI, coronary artery
occlusion, acute coronary syndrome, abnormal cardiac stress test,
cardiomyopathy stress, unstable angina and coronary artery stenosis.
cIncluded: acute renal failure, renal failure, renal impairment and azotemia.
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event-free survival rate decreased with each additional line of
therapy.5 It has been hypothesized that the decline in event-
free survival rate with consecutive regimens reflects acquired
drug resistance and the presence at relapse of tumor cells
with an aggressive phenotype.5,12 Resistance to the same
agent or class of agent may have affected absolute efficacy
outcomes in patients previously exposed to bortezomib or
lenalidomide in the ASPIRE study. Although carfilzomib has
been shown to be effective in patients failing bortezomib-
based regimens and to be a more active proteasome inhibitor
compared with bortezomib,13,14 cross-resistance between
these two proteasome inhibitors may exist.12 In the pivotal
phase 2 study of single-agent carfilzomib in patients with
relapsed and refractory MM, the ORR was lower in patients with
⩾ 2 vs o2 previous lines of bortezomib-based therapy (18.5%
vs 29.5%).15
KRd reduced the risk of disease progression or death vs Rd
across all subgroups analyzed. This benefit was most prominent
in patients refractory to thalidomide (HR 0.599; 95% CI: 0.390,
0.918; P= 0.0089) likely due to the relatively short median PFS
observed in the Rd arm. The benefit of KRd vs Rd was least evident
in patients with disease refractory to bortezomib (HR 0.799; 95%
CI: 0.492, 1.297; P= 0.1810), which is expected, given possible
cross-resistance between bortezomib and carfilzomib. In addition,
patients who were refractory to lenalidomide had only a 2-month
improvement in median PFS with KRd vs Rd.
The safety profile of KRd vs Rd in patients with 1 and ⩾ 2
previous lines of therapy was consistent with those reported for
the overall population,7 and no new or clinically significant safety
signals were identified. In patients with 1 or⩾ 2 previous lines of
therapy, cardiac and renal AEs were observed at rates consistent
with those of previous carfilzomib studies.6,16 Although patients
with MM have been found to develop an increasing number of
comorbidities and disease-related complications with additional
lines of therapy,3 the safety profile of KRd in patients with 1 or ⩾ 2
previous lines of therapy was similar.
In addition to carfilzomib, there are many new approved
agents for relapsed or refractory MM including ixazomib,
elotuzumab and daratumumab. Thus, it will be important for
future studies to understand how to best utilize these agents to
optimize their benefits in treating patients with relapsed or
refractory MM. Future trials evaluating combinations of these
agents, including those combining daratumumab and carfilzo-
mib, may also provide important information regarding optimal
treatment strategies.
In conclusion, this subgroup analysis of the ASPIRE study
indicated that KRd had a favorable benefit–risk profile compared
with Rd, irrespective of previous treatment history. KRd should be
considered an appropriate treatment option for patients in their
first relapse, those who have ⩾ 2 previous lines of therapy, and
those previously exposed to and/or refractory to bortezomib,
thalidomide or lenalidomide.
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